Figure S2 from Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Year: 2023
Type: other
Abstract: Differential binding of icotinib for L858R vs exon19del mutant EGFR. The green represents icotinib; the gray represents pocket residues; the blue represents αC-helix; the red represents delE746-A750; the yellow dotted line indicates hydrogen bond; the Dark green dotted line represents the cation-pi interaction; the GK means gatekeeper.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361815887